Recent advances on dark and light-activated cytotoxity of imidazole- containing ruthenium complexes

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 4, 2016, Pages 272-289

  Liu, Ping ^a   Jia, Jia ^a   Zhao, Yue ^a   Wang, Ke Zhi ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

Author keywords

Anticancer agent; Cytotoxity; DNA; Imidazole; Photocytotoxity; Ruthenium

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IMIDAZOLE; IMIDAZOLE CONTAINING RUTHENIUM COMPLEX; IMIDAZOLE DERIVATIVE; REACTIVE OXYGEN METABOLITE; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG; COORDINATION COMPOUND; DIMETHYL SULFOXIDE; DNA; IMIDAZOLIUM-BIS(IMIDAZOLE)DIMETHYLSULFOXIDEIMIDAZOTETRACHLORORUTHENATE(III); ORGANOMETALLIC COMPOUND; RUTHENIUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CYTOTOXICITY; DARKNESS; DNA BINDING; DOSIMETRY; HEPG2 CELL LINE; HL 60 CELL LINE; HT 29 CELL LINE; HUMAN; IC50; LIGHT; MCF 7 CELL LINE; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; METABOLISM; MOLECULAR MODEL; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; COORDINATION COMPLEXES; DIMETHYL SULFOXIDE; DNA; HUMANS; IMIDAZOLES; LIGHT; MODELS, MOLECULAR; NEOPLASMS; ORGANOMETALLIC COMPOUNDS; RUTHENIUM;

EID: 84958953801     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666151120120524     Document Type: Article

References (72)

1. Pinto, A. L.; Lippard, S. J. Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta, 1985, 780(3), 167-180.
2. Clarke, M. J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2003, 236(1), 209-233.
3. Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem., 2006, 13(9), 1085-1107.
4. Ang, W. H.; Dyson, P. J. Classical and non-classical rutheniumbased anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem., 2006, 20, 4003-4018.
5. Dyson, P. J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans., 2006, 36, 1929-1933.
6. Bergamo, A.; Sava, G. Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans., 2007, 13, 1267-1272.
7. Bergamo, A.; Sava, G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans., 2011, 40, 7817-7823.
8. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1(6), 458-470.
9. Liu, Y.; Chen, T.; Liu, J.; Wong, Y. S. Identification of fluorescent ruthenium complexes containing imidazole derivatives as a new class of apoptosis inducers by living cell real-time imaging. Med. Chem. Commun., 2013, 4(5), 865-869.
10. Mestroni, G.; Alessio, E.; Sava, G.; Pacor, S.; Coluccia, M.; Boccarelli, Water-soluble ruthenium(III)-dimethyl sulfoxlde complexes: chemical behaviour and pharmaceutical properties. Met.-Based Drugs, 1994, 1(1), 41-63.
11. Sava, G.; Capozzi, I.; Clerici, K.; Gagliardi, G.; Alessio, E.; Mestroni, G. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin. Exp. Metastasis, 1998, 16(4), 371-379.
12. Rademaker-Lakhai, J. M.; van den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res., 2004, 10, 3717-3727.
13. Kaufmann, S. H.; Hengartner, M. O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol., 2001, 11(12), 526-534.
14. Kang, K. B.; Zhu, C.; Yong, S. K.; Gao, Q.; Wong, M. C. Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Mol. Cancer, 2009, 8, 66.
15. Abedin, M. J.; Wang, D.; McDonnell, M. A.; Lehmann, U.; Kelekar, A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ., 2007, 14(3), 500-510.
16. Pizarro, A. M.; Sadler, P. J. Unusual DNA binding modes for metal anticancer complexes. Biochimie, 2009, 91(10), 1198-1211.
17. Palchaudhuri, R.; Hergenrother, P. J. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr. Opin. Biotech., 2007, 18(6), 497-503.
18. Brabec, V.; Novakova, O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist. Updates, 2006, 9(3), 111-122.
19. Chaires, J. B. Drug-DNA interactions. Curr. Opin. Struct. Biol., 1998, 8(3), 314-320.
20. Hall, J. P.; O'Sullivan, K.; Naseer, A.; Smith, J. A.; Kelly, J. M.; Cardin, C. J. Structure determination of an intercalating ruthenium dipyridophenazine complex which kinks DNA by semiintercalation of a tetraazaphenanthrene ligand. Proc. Natl. Acad. Sci. USA, 2011, 108(43), 17610-17614.
21. Zeglis, B. M.; Pierre, V. C.; Barton, J. K. Metallo-intercalators and metallo-insertors. Chem. Commun., 2007, 44, 4565-4579.
22. Hall, J. P.; O'Sullivan, K.; Naseer, A.; Smith, J. A.; Kelly, J. M.; Cardina, C. J. Structure determination of an intercalating ruthenium dipyridophenazine complex which kinks DNA by semiintercalation of a tetraazaphenanthrene ligand. Proc. Natl. Acad. Sci. USA, 2011, 108(43), 17610-17614.
23. Turro, C. To intercalate or semiintercalate, or both?. Proc. Natl. Acad. Sci. USA, 2011, 108(43), 17573-17574.
24. Wheate, N. J.; Brodie, C. R.; Collins, J. G.; Kemp, S.; Aldrich-Wright, J. R. DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis. Mini Rev. Med. Chem., 2007, 7(6), 627-648.
25. Bischoff, G.; Hoffmann, S. DNA-binding of drugs used in medicinal therapies. Curr. Med. Chem., 2002, 9(3), 321-348.
26. Song, H.; Kaiser, J. T.; Barton, J. K. Crystal structure of Δ-[Ru(bpy)2dppz]2+ bound to mismatched DNA reveals side-by-side metalloinsertion and intercalation. Nat. Chem., 2012, 4(8), 615-620.
27. He, Z.; Bu, X.; Eleftheriou, A.; Zihlif, M.; Qing, Z.; Stewart, B. W.; Wakelin, L. P. G. DNA threading bis(9-aminoacridine-4-carboxamides): Effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest. Bioorg. Med. Chem., 2008, 16(8), 4390-4400.
28. Onfelt, B.; Gostring, L.; Lincoln, P.; Norden, B.; Onfelt, A. Cell studies of the DNA bis-intercalator Δ-Δ [μ-C4(cpdppz)2-(phen)4Ru2]4+: toxic effects and properties as a light emitting DNA probe in V79 Chinese hamster cells. Mutagenesis, 2002, 17(4), 4317-320.
29. Ju, C. C.; Zhang, A. G.; Yuan, C. L.; Zhao, X. L.; Wang, K. Z. The interesting DNA-binding properties of three novel dinuclear Ru(II) complexes with varied lengths of flexible bridges. J. Inorg. Biochem., 2011, 105(3), 435-443.
30. Schatzschneider, U.; Niesel, J.; Ott, I.; Gust, R.; Alborzinia, H.; Wolfl, S. Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N-N)]Cl2 with N-N = bpy, phen, dpq, dppz, and dppn. Chem. Med. Chem., 2008, 3(7), 1104-1109.
31. Yuan, F.; Chen, X.; Liu, Y.; Zhang, T.; Sun, D.; Liu, J. Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin. Chirality, 2012, 24 (2), 174-180.
32. Shi, S.; Liu, J.; Li, J.; Zheng, K. C.; Huang, X. M.; Tan, C. P.; Chen, L. M.; Ji, L. N. Synthesis, characterization and DNA-binding of novel chiral complexes o-and--[Ru(bpy)2L]2+ (L = o-mopip and p-mopip). J. Inorg. Biochem., 2006, 100(3), 385-395.
33. Liu, J.; Zheng, W.; Shi, S.; Tan, C.; Chen, J.; Zheng, K.; Ji, L. Synthesis, antitumor activity and structure-activity relationships of a series of Ru (II) complexes. J. Inorg. Biochem., 2008, 102(2), 193-202.
34. Tan, L. F.; Song, F. C.; Zou, X. Q.; Ling, X. L. Nucleic acid binding behaviors and cytotoxic properties of a Ru (II) complex. DNA Cell Biol., 2011, 30(5), 277-285.
35. Huang, H. L.; Liu, Y. J.; Zeng, C. H.; He, L. X.; Wu, F. H. In vitro cytotoxicity, apoptosis, DNA-binding, and antioxidant activity studies of ruthenium (II) complexes. DNA Cell Biol., 2010, 29(5), 261-270.
36. Liu, Y. J.; Zeng, C. H.; Liang, Z. H.; Yao, J. H.; Huang, H. L.; Li, Z. Z.; Wu, F. H. Synthesis of ruthenium (II) complexes and characterization of their cytotoxicity in vitro, apoptosis, DNAbinding and antioxidant activity. Eur. J. Med. Chem., 2010, 45(7), 3087-3095.
37. Lin, G. J.; Li, Z. Z.; Yao, J. H.; Huang, H. L.; Xie, Y. Y.; Liu, Y. J. Cytotoxicity in vitro, apoptosis, cellular uptake, cell cycle distribution, mitochondrial membrane potential detection, DNA binding, and photocleavage of ruthenium (II) complexes. Aust. J. Chem., 2013, 66(5), 555-563.
38. Tan, C. P.; Lai, S. S.; Wu, S. H.; Hu, S.; Zhou, L. J.; Chen, Y.; Wang, M. X.; Zhu, Y. P.; Lian, W.; Peng, W. L.; Ji, L. N.; Xu, A. L. Nuclear permeable ruthenium (II) β-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis. J. Med. Chem., 2010, 53(21), 7613-7624.
39. Zhao, X. L.; Li, Z. S.; Zhang, A. G.; Liu, P.; Song, X. M.; Wang, K. Z. pH and DNA luminescence switching, DNA photocleavage and cytotoxic properties of two thiophene-containing ruthenium (II)complexes. Eur. J. Med. Chem., 2014, 87, 10-22.
40. Luo, Z.; Yu, L.; Yang, F.; Zhao, Z.; Yu, B.; Lai, H.; Wong, K.; Ngai, S. M.; Zheng, W.; Chen, T. Ruthenium polypyridyl complexes as inducer of ROS-mediated apoptosis in cancer cells by targeting thioredoxin reductase. Metallomics, 2014, 6(8), 1480-1490.
41. Seelig, M. H.; Berger, M. R.; Keppler, B. K. Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats. J. Cancer Res. Clin. Oncol., 1992, 118(3), 195-200.
42. Antonarakis, E. S.; Emadi, A. Ruthenium-based chemotherapeutics: are they ready for prime time?. Cancer Chemoth. Pharm., 2010, 66(1), 1-9.
43. Bergamo, A.; Gaiddon, C.; Schellens, J. H. M.; Beijnen, J. H.; Sava, G. J. Approaching tumour therapy beyond platinum drugs: Status of the art and perspectives of ruthenium drug candidates. J. Inorg. Biochem., 2012, 106(1), 90-9.
44. Gava, B.; Zorzet, P.; Spessotto, P.; Cocchietto, M.; Sava, G. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate and down-regulation of tumor cell invasion. J. Pharmacol. Exp. Ther., 2006, 317(1), 284-291.
45. Pluim, D.; van Waardenburg, R. C. A. M.; Beijnen, J. H.; Schellens, J. H. M. Cytotoxicity of the organic ruthenium anticancer drug NAMI-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother. Pharmacol., 2004, 54, 71-78.
46. Sava, G.; Pacor, S.; Bergamo, A.; Cocchieto, M.; Mestroni, G.; Alessio, E. Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chem. Biol. Interact., 1995, 95(1-2), 109-126.
47. Sava, G.; Capozzi, I.; Bergamo, A.; Gagliardi, R.; Cocchieto, M.; Masiero, L.; Onisto, M.; Alessio, E.; Mestroni, G.; Garbisa, S. Down regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an antimetastatic ruthenium complex. Int. J. Cancer, 1996, 68(1), 60-66.
48. Sava, G.; Alessio, E.; Bergamo, A.; Mestroni, G. Sulfoxide ruthenium complexes. Non toxic tools for the selective treatment of solid tumor metastasis. Top. Bioinorg. Chem., 1999, 1, 143-169.
49. Sava, G.; Frausin, F.; Cocchietto, M.; Vita, F.; Podda, E.; Spessotto, P.; Furlani, A.; Scarcia, V.; Zabucchi, G. Actindependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. Eur. J. Cancer, 2004, 40(9), 1383-1396.
50. Frausin, F.; Scarcia, V.; Cochietto, M.; Furlani, A.; Serli, B.; Alessio, E.; Sava, G. Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells. J. Pharmacol. Exp. Ther., 2005, 313(1), 227-233.
51. Pacor, S.; Zorzet, S.; Cocchietto, M.; Bacac, M.; Vadori, M.; Turrin, C.; Gava, B.; Castellarin, A.; Sava, G. Intratumoral NAMIA Treatment Triggers Metastasis Reduction, Which Correlates to CD44 Regulation and Tumor Infiltrating Lymphocyte Recruitment. Pharmacol. Exp. Ther., 2004, 310(2), 737-744.
52. Sava, G.; Zorzet, S.; Turrin, C.; Vita, F.; Soranzo, M. R.; Zabucchi, G.; Cocchietto, M.; Bergamo, A.; DiGiovone, S.; Pezzoni, G.; Sartor, L.; Garbisa, S. Dual Action of NAMI-A in Inhibition of Solid Tumor Metastasis: Selective Targeting of Metastatic Cells and Binding to Collagen. Clin. Cancer Res., 2003, 9(5), 1898-1905.
53. Vacca, A. A.; Bruno, M.; Boccarelli, A.; Coluccia, M.; Ribatti, D.; Bergamo, A.; Garbisa, S.; Sartor, L.; Sava, G. Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br. J. Cancer, 2002, 86(6), 993-998.
54. Griffith, D.; Cecco, S.; Zangrando, E.; Bergamo, A.; Sava, G.; Marmion, C. J. Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. J. Bio. Inorg. Chem., 2008, 13(4), 511-520.
55. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem., 2004, 4(15), 1525-35.
56. Groessl, M.; Reisner, E.; Hartinger, C. G.; Eichinger, R.; Semenova, O.; Timerbaev, A. R.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K. Structure-Activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1, 2, 4-triazole, 4-amino-1, 2, 4-triazole, and 1-methyl-1, 2, 4-triazole): aquation, redox Properties, protein binding, and antiproliferative activity. J. Med. Chem., 2007, 50(9), 2185-2193.
57. Pillozzi, S.; Gasparoli, L.; Stefanini, M.; Ristori, M.; D'Amico, M.; Alessio, E.; Scaletti, F.; Becchetti, A.; Arcangeli, A.; Messori, L. NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3. 1 channels. Dalton Trans., 2014, 43(32), 12150-12155.
58. Cardoso, C. R.; Lima, M. V. S.; Cheleski, J.; Peterson, E. J.; Venancio, T.; Farrell, N. P.; Carlos, R. M. Luminescent ruthenium complexes for theranostic applications. J. Med. Chem., 2014, 57(11), 4906-4915.
59. Antony, S.; Morris, J. C.; Bell, T. D. M.; Brown, T.; Spiccia, L.; Harris, H. H. The H. G. smith award article: fluorescent analogues of NAMI-A: synthesis, characterisation, fluorescent properties, and preliminary biological studies in human lung cancer cells. Aust. J. Chem., 2014, 67(12), 1711-1717.
60. Blunden, B. M.; Rawal, A.; Lu, H.; Stenzel, M. H. Superior chemotherapeutic benefits from the ruthenium-based antimetastatic drug NAMI-A through conjugation to polymeric micelles. Macromolecules, 2014, 47(5), 1646-1655.
61. Liu, P.; Liu, J.; Zhang, Y. Q.; Wu, B. Y.; Wang, K. Z. Synthesis, DNA binding and photocleavage, and celluar uptake of an alkyl chain-linked dinuclear ruthenium (II) complex. J. Photochem. Photobiol. B: Biol., 2015, 143, 89-99.
62. Zhao, X. L.; Li, Z. S.; Zheng, Z. B.; Zhang, A. G.; Wang, K. Z. pH luminescence switch, DNA binding and photocleavage, and cytotoxicity of a dinuclearruthenium complex. Dalton Trans., 2013, 42(16), 5764-5777.
63. Zheng, Z. B.; Wu, Y. Q.; Wang, K. Z.; Li, F. Y. pH luminescence switching, dihydrogen phosphate sensing, and cellular uptake of a heterobimetallic ruthenium(II)-rhenium(I) complex. Dalton Trans., 2014, 43(8), 3273-3284.
64. Stephenson, M.; Reichardt, C.; Pinto, M.; Wachtler, M.; Sainuddin, T.; Shi, G.; Yin, H.; Monro, S.; Sampson, E.; Dietzek, B.; McFarland, S. A. Ru(II) dyads derived from 2-(1-pyrenyl)-1Himidazo [4, 5-f ][1, 10] phenanthroline: versatile photosensitizers for photodynamic applications. J. Phys. Chem. A, 2014, 118(45), 10507-10521.
65. Shi, G.; Monro, S.; Hennigar, R.; Colpitts, J.; Fong, J.; Kasimova, K.; DeCoste, R.; Spencer, C.; Chamberlain, L.; Mandel, A.; Lilge, L.; McFarland, S. A. Ru(II) dyads derived from L-oligothiophenes: A new class of potent and versatile photosensitizers for PDT. Coord. Chem. Rev., 2015, 282-283, 127-138.
66. Song, H.; Kaiser, J. T.; Barton, J. K. Crystal structure of Δ-[Ru(bpy)2dppz]2+ bound to mismatched DNA reveals side-by-side metalloinsertion and intercalation. Nat. Chem., 2012, 4(8), 615-620.
67. Chen, T.; Liu, Y.; Zheng, W. J.; Liu, J.; Wong, Y. S. Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells. Inorg. Chem., 2010, 49(14), 6366-6368.
68. Xu, L., Chen, X.; Wu, J.; Wang, J.; Ji, L.; Chao, H. Dinuclear ruthenium(II) complexes that induce and stabilise G-quadruplex DNA. Chem. Eur. J., 2015, 21(10), 4008-4020.
69. Martinez, A.; Suarez, J.; Shand, T.; Magliozzo, R. S.; Sanchez-Delgado, R. A. Interactions of arene-Ru(II)-chloroquine complexes of known antimalarial and antitumor activity with human serum albumin (HSA) and transferrin. J. Inorg. Biochem., 2011, 105(1), 39-45.
70. Bindoli, A.; Rigobello, M. P.; Scutari, G.; Gabbiani, C.; Casini, A.; Messori, L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord. Chem. Rev., 2009, 253(11-12), 1692-1707.
71. Fricker, S. P. Cysteine proteases as targets for metal-based drugs. Metallomics, 2010, 2(6), 366-377.
72. Butt, T. R.; Karathanasis, S. K. Transcription factors as drug targets: opportunities for therapeutic selectivity. Gene Expr., 1995, 4(6), 319-36.